A Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic Parkinson’s Disease Post author: Post published:March 30, 2026 Post category: Continue ReadingA Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic Parkinson’s Disease
Clinical Development of ETX101, a Gene Regulation Therapy for SCN1A+ Dravet Syndrome Post author: Post published:March 30, 2026 Post category: Continue ReadingClinical Development of ETX101, a Gene Regulation Therapy for SCN1A+ Dravet Syndrome
Phase I/II Clinical Trial for CMT4J Post author: Post published:March 30, 2026 Post category: Continue ReadingPhase I/II Clinical Trial for CMT4J
Optogenetic Gene Therapy for Treatment of Retinitis Pigmentosa Post author: Post published:March 30, 2026 Post category: Continue ReadingOptogenetic Gene Therapy for Treatment of Retinitis Pigmentosa
Phase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD) Post author: Post published:March 30, 2026 Post category: Continue ReadingPhase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD)
TRX103 for prevention of GvHD in patients receiving HLA mismatched HSCT for the treatment of hematologic malignancies Post author: Post published:March 30, 2026 Post category: Continue ReadingTRX103 for prevention of GvHD in patients receiving HLA mismatched HSCT for the treatment of hematologic malignancies
Inhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy Post author: Post published:March 30, 2026 Post category: Continue ReadingInhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy
The UCLA Delayed Immunological Tolerance after Kidney Transplantation Program Post author: Post published:March 30, 2026 Post category: Continue ReadingThe UCLA Delayed Immunological Tolerance after Kidney Transplantation Program
Phase 1b Study of TN-401 in Adults with PKP2 Mutation-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Post author: Post published:March 30, 2026 Post category: Continue ReadingPhase 1b Study of TN-401 in Adults with PKP2 Mutation-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Selective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies Post author: Post published:March 30, 2026 Post category: Continue ReadingSelective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies
